tolllik
receptor
tlr
highli
conserv
type
membran
protein
initi
multipl
transient
gene
transcript
result
innat
adapt
immun
respons
essenti
immun
respons
trigger
common
tlr
pattern
recognit
receptor
microbi
product
express
cytoplasm
carboxytermin
domain
adapt
protein
cascad
induc
activ
induc
transient
transcript
respons
tlr
except
use
adapt
initi
proinflammatori
cascad
use
toll
receptor
induct
factor
adapt
initi
differ
cytosol
adapt
cascad
doublestrand
rna
agonist
pathway
induc
nfkb
type
interferon
respons
use
doublestrand
rna
agonist
rintatolimod
demonstr
signific
unexpect
differ
toxic
respons
rat
primat
mechan
differenti
respons
consist
rel
downregul
nfkb
inflammatori
cytokin
induct
pathway
cynomolgu
monkey
human
observ
system
rat
find
suggest
evalu
agonist
drug
therapi
j
pathol
http
dx
anim
model
timetest
standard
develop
novel
therapeut
potenti
model
adequ
translat
find
use
therapeut
develop
howev
recent
question
report
seok
et
al
found
poor
correl
human
murin
respons
inflammatori
stimuli
includ
respons
trauma
burn
endotoxemia
discord
result
level
gene
express
array
tempor
gene
respons
pattern
major
signal
pathway
respons
injuri
demonstr
across
speci
well
conserv
human
point
toward
inadequ
nonpredict
natur
avail
inflamm
murin
model
may
explain
difficulti
translat
promis
pharmacolog
compound
success
novel
therapi
despit
heterogen
patient
caus
lifethreaten
trauma
report
found
highli
correl
genom
respons
profil
across
patient
popul
across
speci
burn
trauma
endotoxemia
yield
highli
correl
genom
respons
within
speci
across
speci
rodent
human
observ
similar
dissoci
toxic
parallel
proinflammatori
system
tolllik
receptor
induct
innat
immun
respons
tlr
form
famili
class
transmembran
receptor
origin
discov
drosophila
essenti
element
embryogenesi
evolutionari
ancient
system
immun
respons
pathogenassoci
molecular
pattern
pamp
recogn
plant
fish
mice
well
primat
tlr
act
first
line
defens
microbi
pathogen
induct
innat
immun
provid
initi
cellular
orchestr
induct
adapt
immun
respons
provid
specif
humor
support
hemispherx
biopharma
inc
disclosur
wmm
independ
member
board
director
sharehold
hemispherx
biopharma
inc
cfn
consult
hemispherx
biopharma
inc
wac
chief
execut
offic
member
board
director
sharehold
hemispherx
biopharma
inc
jch
employe
hemispherx
biopharma
inc
dr
medic
director
sharehold
hemispherx
biopharma
inc
rinitatolimod
experiment
drug
whose
clinic
develop
manufactur
fund
hemispherx
biopharma
inc
trade
name
ampligen
cellmedi
immun
mediat
part
inflammatori
cytokin
found
especi
matur
dendrit
cell
dc
central
host
adapt
immun
respons
system
tlr
use
signal
pathway
except
use
trif
pathway
two
doublestrand
rna
dsrna
induc
gene
express
initi
innat
immun
respons
cytosol
helicas
retino
acid
induc
gene
protein
depend
pamp
dsrna
detect
endosom
antigenpres
cell
cell
surfac
select
cell
includ
endotheli
cell
airway
epithelium
express
pattern
consist
sentinel
activ
detect
replic
viru
host
organ
cellular
locat
modul
promot
traffick
differenti
glycosyl
plasma
membran
transcript
upregul
dsrna
address
observ
toxic
heterogen
respons
pamp
across
speci
use
restrict
agonist
much
data
report
doubleblind
clinic
trial
unpublish
openlabel
safeti
trial
rintatolimod
poli
poli
c
u
ampligen
synthet
dsrna
analogu
compos
singl
polypurin
inosin
strand
singl
polypyrimidin
cytosin
uridin
strand
assembl
dsrna
structur
maintain
physiolog
condit
typic
hydrogen
bond
purin
pyrimidin
base
pair
introduct
pyrimidin
base
uridin
ratio
polypyrimidin
strand
maintain
doublestrand
structur
allow
recur
site
thermodynam
instabl
nonhydrogen
bond
mismatch
base
uridin
inosin
polypurin
strand
small
differ
structur
howev
restrict
induct
transitori
gene
activ
uniqu
trif
signal
pathway
exclus
dsrna
proinflammatori
depend
figur
use
restrict
specif
rintatolimod
uniqu
trif
pathway
signal
abl
identifi
appar
mechan
discord
toxic
rodent
primat
patient
serum
sampl
two
clinic
trial
conduct
accord
good
clinic
practic
standard
figur
signal
pathway
tlr
helicas
intracellular
pathway
nuclear
signal
transduct
initi
trif
bind
tir
homodim
monom
dimer
bind
dsrna
ligand
activ
trif
initi
two
pathway
first
result
transitori
induct
ifn
second
speciesvari
pathway
rodent
primat
oper
nfkb
dash
line
transient
induc
product
inflammatori
cytokin
adapt
protein
cascad
initi
trif
ikk
ectodomain
consist
horseshoeshap
structur
popul
leucinerich
bsheet
orang
disk
connect
nonord
chain
contain
rnabind
residu
transmembran
ahelic
solid
orang
connect
ectodomain
cytoplasm
tir
domain
dark
green
phosphoryl
tir
bind
trif
initi
adapt
protein
cascad
b
intracellular
pathway
signal
tlr
heterodim
tlr
homodim
divers
pamp
ligand
green
bar
necessarili
accur
placement
dsrna
ligand
use
pathway
triftir
domainecontain
adapterinduc
ifn
kinas
traftnf
receptoreassoci
factor
protein
ikkikb
kinas
inhibitor
ikb
kinas
irfifn
regulatori
transcript
factor
kinas
receptoreinteract
tnfrsf
kinas
american
journal
pathologyajpamjpatholorg
rintatolimod
investig
new
drug
analyz
ginterferon
ifn
tumor
necrosi
factor
tnf
level
assess
acut
chronic
chang
might
associ
rintatolimod
dose
human
protocol
conduct
institut
review
board
review
approv
patient
inform
consent
studi
subject
diagnosi
chronic
fatigu
syndrom
qualifi
particip
met
protocol
entranc
criteria
patient
receiv
rintatolimod
infus
mg
twice
weekli
frozen
serum
sampl
randomli
select
patient
hemispherx
biopharma
openlabel
treatment
protocol
obtain
preinfus
hour
infus
serum
sampl
randomli
select
patient
doubleblind
protocol
amp
obtain
baselin
preinfus
week
earli
termin
patient
termin
particip
week
serum
obtain
clinic
test
site
frozen
ship
hemispherx
biopharma
inc
test
manufactur
facil
new
brunswick
nj
assay
use
commerci
avail
enzymelink
immunosorb
assay
kit
human
ifng
human
tnfa
human
human
supplement
tabl
anim
toxicolog
analys
conduct
requir
investig
new
drug
guidelin
studi
conduct
accord
good
laboratori
practic
procedur
licens
anim
pharmacolog
facil
accord
institut
anim
care
committe
review
approv
dose
rang
conduct
dupont
wilmington
de
bioresearch
sennevil
qc
canada
chronic
toxicolog
studi
conduct
chrysali
cedex
franc
pharamakon
waverli
pa
maximum
toler
dose
mtd
deriv
acut
subacut
doserang
studi
defin
maximum
dose
caus
mortal
moribund
toxic
repeat
dose
studi
conduct
spraguedawley
rat
beagl
dog
cynomolgu
monkey
new
zealand
white
rabbit
dose
rang
mgkg
iv
administ
daili
day
rat
rabbit
twice
weekli
monkey
dog
week
respect
clinic
observ
record
infus
hour
infus
otherwis
twice
daili
complet
postmortem
analysi
conduct
includ
gross
microscop
anatom
evalu
use
standard
anim
patholog
procedur
sixmonth
chronic
toxicolog
studi
conduct
use
twiceweekli
dose
mgkg
rintatolimod
similar
procedur
assess
acut
inflammatori
cytokin
respons
rintatolimod
administr
conduct
collabor
lovelac
respiratori
research
institut
albuquerqu
nm
hemispherx
biopharma
inc
good
laboratori
practic
use
approv
anim
welfar
protocol
thirtytwo
spraguedawley
rat
infus
twice
weekli
week
mgkg
sampl
cytokin
hour
dose
respect
time
point
infus
requir
sacrific
male
femal
rat
ten
cynomolgu
monkey
dose
week
twice
weekli
dosag
level
serum
sampl
cytokin
measur
obtain
dose
serum
sampl
frozen
assay
correspond
patient
cytokin
use
commerci
avail
enzymelink
immunosorb
assay
kit
supplement
tabl
result
report
basi
manufacturersuppli
standard
yield
lineardos
respons
advers
event
data
rintatolimodand
placebotr
patient
control
studi
chronic
fatigu
syndrom
assess
context
toxicolog
find
advers
event
collect
serial
patient
evalu
studi
subject
particip
prospect
studi
mg
rintatolimod
placebo
infus
twice
weekli
durat
protocol
xray
crystallograph
structur
mous
dimerbioldsrna
complex
human
monom
provid
coordin
model
human
rintatolimod
bound
activ
site
molecular
model
use
accelri
discoveri
suit
softwar
version
accelri
inc
san
diego
ca
dsrna
structur
dimerbioldsrna
complex
mutat
situ
respect
poli
blue
poli
c
u
magenta
chain
maintain
phosphat
backbon
linear
translat
coordin
xray
crystallograph
structur
coordin
human
monom
use
replac
homodim
sever
unaccept
close
van
der
waal
contact
human
crystal
coordin
resolv
altern
rotam
conform
individu
amino
acid
r
group
demonstr
rel
equival
two
ligand
agonist
silico
measur
potenti
energi
ligand
nake
homodim
complex
reduct
potenti
energi
complex
versu
sum
potenti
energi
compon
energi
bind
primari
protein
sequenc
human
genbank
monkey
speci
includ
macaca
mulatta
genbank
macaca
fasiculari
ajpamjpatholorg
american
journal
patholog
genbank
papio
anubi
callithrix
jacchu
saimiri
boliviensi
rodent
includ
hous
mous
genbank
musculu
rat
genbank
norvegicu
dog
genbank
xp
lupu
familiari
rabbit
genbank
cuniculu
align
use
crystal
w
softwar
version
provid
dnastar
madison
wi
acut
doserang
toxicolog
analysi
complet
rabbit
dog
rat
monkey
tabl
mtd
defin
highest
acut
dosag
associ
induct
moribund
state
mortal
observ
rang
two
order
magnitud
rabbit
prove
sensit
rintatolimod
mtd
mgkg
per
dose
dog
rat
toler
mtd
mgkg
per
dose
respect
cynomolgu
monkey
substanti
toler
rintatolimod
mtd
mgkg
per
dose
result
surprisingli
differenti
acut
toxic
nonhuman
primat
least
suscept
rintatolimod
toxic
clinic
develop
rintatolimodenvis
chronic
system
dose
agonist
prolong
period
treatment
chronic
fatigu
syndrom
meet
regulatori
requir
guidanc
industri
nonclin
safeti
evalu
drug
biolog
combin
us
depart
health
human
servic
food
drug
administr
center
drug
evalu
research
cder
http
wwwfdagovohrmsdocket
last
access
februari
chronic
toxicolog
studi
conduct
spraguedawley
rat
cynomolgu
monkey
anim
dose
similar
human
schedul
twiceweekli
infus
rintatolimod
mgkg
per
dose
expect
nonleth
basi
acut
toxic
studi
dose
level
determin
human
dose
mg
per
infus
approxim
mgkg
averages
patient
result
two
chronic
toxicolog
studi
consist
find
acut
toxicolog
dose
tabl
although
lethal
rat
cours
studi
commonli
observ
rat
extrem
sensit
multipl
organ
dose
regimen
mani
anim
group
surviv
dose
period
rat
dosedepend
liver
renal
toxic
observ
three
dosag
group
addit
find
rat
includ
anemia
polychromasia
increas
alkalin
phosphatas
profound
elev
hepat
transaminas
histopatholog
featur
consist
clinic
analyt
dosedepend
toxic
observ
dose
group
hepatocellular
degener
bile
duct
hyperplasia
interstiti
nephriti
renal
tubular
dilat
lymphoid
deplet
hyperpigment
probabl
hemosiderin
note
spleen
extramedullari
hematopoiesi
occasion
miscellan
organ
inflamm
also
note
dose
group
contrast
monkey
toler
cours
without
signific
toxic
except
occasion
vomit
associ
infus
mgkg
group
transient
elev
hepat
transaminas
highdos
group
associ
unexplain
decreas
alkalin
phosphatas
monkey
coagul
paramet
prolong
highdos
monkey
group
histopatholog
find
monkey
except
increas
myelopoiesi
marrow
follicular
thyroid
hyperplasia
mgkg
dose
group
thyroid
morpholog
observ
nonhuman
primat
correl
increas
thyroidstimul
hormon
thyroxin
suggest
central
effect
pituitari
caus
thyroid
hyperact
observ
hyperplasia
use
clinicalgrad
formul
poli
poli
c
u
rintatolimod
ampligen
also
found
discord
rodent
human
inflammatori
respons
demonstr
nonhuman
primat
model
cynomolgu
monkey
human
similarli
minor
toxic
compar
rodent
model
spraguedawley
rat
model
inflamm
explor
seok
et
al
substanti
betweenspeci
differ
appar
contrast
rodent
sensit
endotoxin
magnitud
less
human
rintatolimodmedi
pathway
rodent
highli
sensit
wherea
primat
rel
toler
data
summar
tabl
demonstr
minim
associ
rodent
toxicolog
find
human
experi
low
incid
transient
liver
american
journal
pathologyajpamjpatholorg
function
test
abnorm
seen
human
ie
easili
manag
dose
reduct
mg
patient
experi
rigor
flulik
symptom
associ
infus
vomit
note
highdos
monkey
infus
gener
toxic
observ
rat
thyroid
abnorm
observ
monkey
toxic
trial
detect
human
clinic
data
set
thu
human
experi
similar
monkey
although
major
find
pituitarydepend
thyroid
hyperact
note
monkey
seen
human
human
monkey
differ
substanti
patholog
respons
compar
rodent
unexpect
differenti
toxic
observ
rat
nonhuman
primat
prompt
examin
inflammatori
cytokin
gifn
tnfa
associ
infus
agonist
rintatolimod
preclin
studi
rat
cynomolgu
monkey
assess
induct
three
inflammatori
cytokin
well
measur
serum
respons
three
dosag
level
mgkg
rintatolimod
administ
iv
infus
time
point
respons
initi
infus
rat
gave
strongest
system
signal
illustr
tabl
express
pattern
consist
although
less
intens
later
time
point
monkey
exhibit
minim
evid
system
cytokin
product
minim
ifng
respons
observ
significantli
differ
rat
highest
mgkg
dose
level
gener
small
respons
one
monkey
contrast
rat
show
system
cytokin
respons
signal
present
three
inflammatori
cytokin
even
lowest
mgkg
dose
speci
differ
system
inflammatori
cytokin
express
statist
signific
cytokin
p
comparison
human
serum
obtain
patient
particip
concurr
openlabel
clinic
studi
chronic
fatigu
syndrom
similar
time
cours
anim
pharmacolog
characterist
quantifi
panel
cytokin
human
clinic
trial
patient
dose
mg
rintatolimod
iv
minut
similar
monkey
respons
serum
cytokin
increas
minim
express
ifng
highest
aggreg
larg
sd
tabl
final
assess
evid
chronic
system
cytokin
chang
week
time
point
obtain
tabl
illustr
result
similar
monkey
one
patient
exhibit
rel
high
system
tnfa
level
system
inflammatori
cytokin
observ
rat
correl
signific
acut
chronic
vivo
toxic
dose
elicit
detect
system
inflammatori
cytokin
minim
toxic
primat
moreov
elev
thyroid
activ
cynomolgu
monkey
detect
human
system
signal
cytokin
chang
associ
week
rintatolimod
mg
per
dose
iv
twice
weekli
evidenc
human
dc
show
phenotyp
chang
associ
exposur
rintatolimod
includ
shift
matur
profil
local
releas
cytokin
il
ifng
tnfa
chemokin
monocyt
chemoattract
macrophag
inflammatori
microenviron
cultur
supernat
demonstr
commun
system
elev
inflammatori
cytokin
observ
rat
monkey
human
local
elev
microenviron
induc
rintatolimod
rare
detect
system
differ
magnitud
respons
differ
human
appear
respons
least
part
rel
lack
toxic
primat
toxic
associ
overwhelm
infect
associ
system
cytokin
storm
elev
measur
circul
cytokin
lack
system
cytokin
detect
consist
observ
minim
toxic
primat
contrast
signific
toxic
observ
nonprim
rat
toxic
correl
system
cytokin
level
lack
primat
toxic
similarli
correl
lack
signific
system
inflammatori
cytokin
level
vitro
data
howev
demonstr
cell
express
respond
dsrna
differ
system
cytokin
level
microenviron
quantit
inflammatori
cytokin
observ
system
circul
rat
associ
extrem
toxic
analog
toxic
seen
human
lethal
viral
infect
highli
pathogen
avian
influenza
sever
acut
respiratori
syndrom
sar
coronaviru
inflammatori
cytokin
storm
standard
human
bioactiv
dose
approxim
mg
kg
associ
substanti
system
toxic
rodent
dose
three
time
higher
often
lethal
poli
poli
c
associ
signific
human
toxic
observ
rintatolimod
examin
whether
dissoci
toxic
human
relat
affin
dsrna
ligand
model
predict
rel
bind
constant
poli
poli
c
versu
mismatch
poli
c
analogu
figur
demonstr
silico
molecular
model
rintatolimod
bound
human
ectodomain
form
homodim
structur
close
amino
acid
contact
variabl
nonhel
segment
noncoval
contact
provid
collect
energet
bind
form
activ
homodim
poli
poli
c
demonstr
equival
silico
energet
bind
rintatolimod
sever
structur
mismatch
base
poli
c
strand
tabl
insert
uridin
poli
c
strand
poli
poli
c
variou
ratio
cu
signific
effect
bind
affin
thu
biolog
differ
observ
rintatolimod
poli
poli
c
attribut
differenti
affin
bind
advers
event
data
rintatolimod
placebotr
patient
wellcontrol
studi
chronic
fatigu
syndrom
assess
context
toxicolog
find
advers
event
collect
serial
patient
evalu
studi
subject
particip
prospect
studi
rintatolimod
mg
placebo
infus
twice
weekli
durat
studi
elev
lft
result
denot
alanin
aminotransferas
aspart
aminotransferas
greater
three
time
upper
limit
normal
patient
discontinu
secondari
abnorm
lft
result
lft
liver
function
test
tsh
thyroidstimul
hormon
thyroxin
american
journal
pathologyajpamjpatholorg
evalu
rabbit
cuniculu
dog
c
lupu
familiari
rat
r
norvegicu
monkey
code
sequenc
rel
human
standard
differ
speci
ortholog
rabbit
dog
rat
show
sequenc
nonident
supplement
figur
monkey
highli
homolog
five
speci
analyz
supplement
figur
major
diverg
anticip
old
world
mulatta
fasiculari
cynomolgu
p
anubi
baboon
new
world
c
jacchu
boliviensi
monkey
specif
sequenc
differ
cynomolgu
monkey
rat
rel
human
list
tabl
express
protein
monkey
rat
similar
total
amino
acid
composit
residu
respect
versu
z
differ
rat
monkey
cytokin
level
across
three
dosag
level
use
jonckheereterpstra
test
two
side
infus
provid
approxim
mgkg
averag
dose
high
mean
sd
valu
secondari
one
patient
valu
remov
patient
result
mean
valu
ajpamjpatholorg
american
journal
patholog
shorter
human
residu
expect
monkey
greater
homolog
human
mouserat
sequenc
note
mous
rat
homolog
rodent
sequenc
differ
versu
human
leucin
rich
repeat
differ
human
monkey
present
leucin
rich
repear
endodomain
highli
conserv
three
speci
ectodomain
probabl
critic
cell
signal
function
cytoplasm
toll
receptor
tir
suggest
monkey
rodent
signal
domain
may
greater
function
similar
human
basi
larg
dispar
residu
length
human
versu
monkey
rodent
tir
endodomain
rintatolimod
provid
uniqu
tool
allow
us
dissect
differenti
effect
speci
system
respons
activ
although
poli
poli
c
serv
ligand
prototyp
agonist
experiment
purpos
also
activ
dsrnasens
cytosol
helicas
substitut
mismatch
base
uridin
poli
c
strand
rintatolimod
inactiv
ligand
activ
cytosol
helicas
maintain
agonist
activ
helicas
act
inflammatori
pathway
use
mammalian
tlr
except
use
trif
adapt
initi
innat
immun
respons
figur
illustr
pattern
recognit
ectodomain
tlr
cytoplasm
adapt
pathway
respons
pleiotroph
effect
figur
depict
pathway
use
figur
depict
pathway
use
tlr
helicas
except
toxicolog
analysi
demonstr
system
dosedepend
inflammatori
cytokin
respons
rat
although
examin
inflammatori
cytokin
respons
rabbit
dog
lack
avail
test
kit
cytokin
examin
believ
would
observ
similar
quantit
cytokin
respons
dog
observ
rat
rabbit
ntermin
bind
opposit
end
dsrna
minimum
length
bp
requir
interact
essenti
residu
activ
intracellular
signal
amino
acid
requir
bind
rintatolimod
shown
cpk
van
der
waal
radii
associ
phosphat
backbon
b
homodim
complex
rintatolimod
seen
long
axi
dsrna
homodim
repres
structur
element
blue
arrow
signifi
direct
leucin
repeat
bsheet
red
cylind
signifi
ahelic
poli
strand
rintatolimod
blue
poli
c
u
strand
magenta
cytidin
green
uridin
american
journal
pathologyajpamjpatholorg
sensit
rintatolimod
mechan
may
simpli
induc
system
cytokin
level
although
toxic
mechan
may
involv
howev
signific
detect
system
inflammatori
cytokin
either
monkey
human
data
indic
parallel
intracellular
ifn
nfkb
transcript
pathway
speci
depend
magnitud
respons
primat
cell
cultur
respond
rintatolimod
biosynthesi
ifn
inflammatori
cytokin
insuffici
vivo
provid
detect
system
respons
lack
system
inflammatori
respons
primat
consist
observ
discord
vivo
toxic
rat
monkey
human
consist
differ
gross
analysi
histopatholog
characterist
observ
speci
case
tlr
pathway
primat
sensit
contrast
primat
much
resili
rodent
inflammatori
cytokin
toxic
induc
trifmedi
activ
redund
helicas
pathway
may
reduc
toxicolog
distinct
speci
agonist
activ
pathway
poli
poli
c
contrast
rintatolimod
potenti
mechan
may
explain
speciesspecif
differenti
toxic
observ
activ
dsrna
appar
analysi
gene
structur
differ
speci
addit
primari
sequenc
differ
rodent
primat
illustr
tabl
rodent
human
gene
structur
remark
dissimilar
proxim
promot
domain
well
isoform
exampl
differenti
function
activ
mice
human
induct
express
murin
macrophag
lipopolysaccharid
lp
ie
seen
human
express
human
blood
cell
includ
monocyt
granulocyt
natur
killer
cell
cell
b
cell
tissu
macrophag
undetect
transcript
level
lp
exposur
seen
myeloid
dc
addit
structur
differ
exist
result
possibl
differenti
isoform
transcript
initi
either
exon
exon
mous
indic
differ
promot
present
human
clone
human
isoform
suggest
altern
previous
unrecogn
splice
pathway
observ
speciesspecif
lp
respons
macrophag
could
confer
consensu
motif
nfkb
bind
present
murin
tlr
promot
absent
human
promot
confirm
later
studi
demonstr
speciesspecif
differ
tissu
express
respons
lp
coincid
presenc
differ
evolutionari
nonconserv
promot
sequenc
speci
howev
despit
overal
nonrelated
promot
sequenc
mrna
express
ortholog
induc
ifn
particularli
ifnb
basal
ifnbeinduc
activ
promot
speci
larg
depend
similar
ifn
regulatori
factor
irf
element
constitut
total
monkeyexpress
contain
residu
versu
residu
human
x
total
rodent
mous
rat
eexpress
contain
residu
versu
residu
human
calcul
accelri
discoveri
studio
softwar
version
use
distancedepend
dielectr
net
interact
energi
energi
complex
minu
energi
compon
poli
c
u
rintatolimod
charmm
gener
forc
field
vdw
van
der
waal
ajpamjpatholorg
american
journal
patholog
bound
recruit
stimul
murin
macrophag
upregul
induc
ifnb
requir
part
janu
kinas
famili
member
also
lp
specif
upregul
express
induct
autocrineparacrin
ifnb
human
howev
ifnb
induc
upregul
block
pretreat
lp
despit
effici
induct
recent
public
provid
addit
evid
differenti
cytokin
respons
mice
human
exposur
human
primari
dc
agonist
dsrna
induc
tnfa
human
macrophag
antiinflammatori
cytokin
induc
tnfa
induc
effect
specif
human
cell
tnfa
induc
dsrna
murin
dc
moreov
differenti
regul
nfkb
murin
versu
human
cell
shown
numer
prior
commun
laboratori
demonstr
nfkb
activ
dsrna
murin
cell
absent
human
dc
macrophag
ikba
degrad
present
murin
cell
differ
ectodomain
human
nonhuman
primat
llr
provid
potenti
mechan
explain
small
differenti
toxic
speci
length
dispar
cytoplasm
signal
domain
rodent
nonhuman
primat
compar
human
may
contribut
small
differ
toxic
observ
monkey
human
numer
report
compar
speci
specif
tlr
respons
especi
includ
mous
human
monkeyhuman
fishdrosophila
human
comparison
agonist
demonstr
similar
cytokin
level
human
chimpanze
versu
baboon
consist
total
dna
sequenc
homolog
small
differ
observ
cynomolgu
monkey
human
although
univers
tlr
respons
larg
conserv
across
primat
chimpanzeespecif
immun
signal
enrich
hivinteract
gene
influenc
hiv
diseas
progress
differ
exist
primat
phenotyp
respons
tlr
agonist
nevertheless
rel
similar
compar
speci
observ
signific
speci
differ
toxic
respons
rintatolimod
restrict
agonist
analysi
dosedepend
toxic
rat
monkey
human
remark
dissimilar
primat
far
resili
stimul
rodent
data
consist
differenti
nuclear
transcript
activ
nfkb
pathway
inflammatori
cytokin
product
primat
play
rel
minor
role
compar
nuclear
ifn
induc
interestingli
rintatolimod
recent
advanc
clinic
therapeut
modul
chronic
fatigu
syndrom
condit
manifest
disord
energi
metabol
symptom
curious
reminisc
toxic
associ
inflammatori
innat
immun
respons
hypothes
therapeut
effect
may
relat
feedback
inhibit
pathway
rintatolimod
specif
activ
discord
toxic
either
direct
equal
problemat
success
clinic
develop
experiment
therapeut
either
place
patient
risk
unexpect
toxic
convers
rais
regulatori
barrier
agent
shown
toxic
sensit
speci
altern
method
vitro
analysi
demonstr
steb
et
al
need
valid
adapt
regulatori
evalu
human
safeti
analog
issu
may
encount
model
retin
diseas
across
speci
context
rnabas
therapeut
recognit
differenti
vivo
toxic
understand
mechan
involv
benefici
ration
design
riskbenefit
analysi
new
pharmacolog
agent
human
use
